NTHI · Insider Trading
NeOnc Technologies Holdings, Inc. Common Stock
Every open-market purchase and sale reported by NTHI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-18 | Keithly Garnett | CFO | Sell | +5,000 | +$16.81K |
| 2026-09-15 | Amir F Heshmatpour | CEO, President | Buy | +50,000 | +$174.79K |
| 2026-09-15 | Keithly Garnett | CFO | Buy | +257 | +$1.00K |
| 2026-09-15 | Thomas C Chen | CEO | Buy | +10,798 | +$40.00K |
| 2026-09-14 | Amir F Heshmatpour | CEO, President | Buy | +37,000 | +$135.62K |
| 2026-08-20 | Thomas C Chen | CEO | Buy | +12,757 | +$70.00K |
| 2026-08-20 | Thomas C Chen | Chief Scientific Officer | Buy | +47,207 | +$192.90K |
| 2026-08-18 | Amir F Heshmatpour | CEO, President | Buy | +9,000 | +$49.86K |
| 2026-08-18 | Thomas C Chen | CEO | Buy | +36,259 | +$140.00K |
| 2026-08-17 | Amir F Heshmatpour | CEO, President | Buy | +15,000 | +$58.58K |
| 2026-07-13 | Nasim Shomali | Director | A | +50,000 | — |
| 2026-05-04 | Amir F Heshmatpour | President | Buy | +10,000 | +$41.59K |
| 2026-04-28 | Amir F Heshmatpour | President | Buy | +10,000 | +$45.18K |
| 2026-04-24 | Yousha Neman-Ebrahim | Chief Clinical Officer | Buy | +500 | +$2.44K |
| 2026-04-24 | Keithly Garnett | CFO | Buy | +300 | +$1.61K |
| 2026-04-23 | Amir F Heshmatpour | President | Buy | +10,000 | +$49.00K |
| 2026-04-13 | David Jr. Suh | Chief Accounting Officer | MIXED | +111,866 | +$1.00K |
| 2026-04-10 | Amir F Heshmatpour | President | Buy | +10,000 | +$48.95K |
| 2026-04-09 | Amir F Heshmatpour | President | Buy | +15,000 | +$82.00K |
| 2026-04-06 | Amir F Heshmatpour | President | Buy | +25,000 | +$153.40K |
| 2025-11-24 | Yousha Neman-Ebrahim | Chief Clinical Officer | Buy | +1,100 | +$7.36K |
| 2025-11-24 | Amir F Heshmatpour | President | Buy | +30,000 | +$184.66K |
| 2025-11-10 | Amir F Heshmatpour | President | A | +1,200,000 | — |
| 2025-06-09 | Yousha Neman-Ebrahim | Chief Clinical Officer | A | +133,000 | — |
| 2025-06-05 | Patrick Walters | COO | MIXED | +10,985 | −$5.68K |
| 2025-06-05 | Ming-Fu (alan) Chiang | Director | MIXED | +103,498 | −$27.66K |
| 2025-06-05 | Thomas C Chen | CEO | MIXED | +36,379 | −$18.80K |
| 2025-06-05 | Amir F Heshmatpour | Director | MIXED | +35,665 | −$18.44K |
| 2025-06-05 | Keithly Garnett | CFO | MIXED | +6,135 | −$3.17K |
| 2025-05-23 | Keithly Garnett | CFO | Buy | +675 | +$4.92K |
| 2025-05-23 | Amir F Heshmatpour | President | Buy | +2,000 | +$14.79K |
| 2025-05-23 | Thomas C Chen | CEO | Buy | +5,468 | +$40.00K |
| 2025-05-22 | Keithly Garnett | CFO | Buy | +90 | +$631 |
| 2025-05-22 | Keithly Garnett | CFO | Buy | +135 | +$976 |
| 2025-05-19 | Keithly Garnett | CFO | Buy | −90 | −$631 |
| 2025-05-19 | Thomas C Chen | CEO | Buy | +400 | +$2.80K |
| 2025-05-19 | Jim Delshad | Director | Buy | +5,100 | +$37.26K |
| 2025-05-19 | Amir F Heshmatpour | President | Buy | +10,000 | +$106.51K |
| 2025-04-08 | Keithly Garnett | CFO | MIXED | +6,135 | −$3.17K |
| 2025-04-08 | Amir F Heshmatpour | Director | MIXED | +35,665 | −$18.44K |
| 2025-04-08 | Thomas C Chen | CEO | MIXED | +36,379 | −$18.80K |
| 2025-04-08 | Patrick Walters | COO | MIXED | +10,985 | −$5.68K |
| 2025-04-08 | Ming-Fu (alan) Chiang | Director | MIXED | +103,498 | −$27.66K |
| 2025-03-28 | Keithly Garnett | CFO | J | −687 | — |
| 2025-03-28 | Patrick Walters | COO | J | −1,231 | — |
| 2025-03-28 | Amir F Heshmatpour | Director | J | −3,996 | — |
| 2025-03-28 | Jim Delshad | Director | A | +50,000 | — |
| 2025-03-28 | Ming-Fu (alan) Chiang | Director | MIXED | +44,006 | — |
| 2025-03-28 | Thomas C Chen | CEO | J | −4,076 | — |
| 2025-03-28 | Steven L. Giannotta | Director | A | +50,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Amir F Heshmatpour | CEO, President | 6,897,020 | $19.45M |
| Patrick Walters | COO | 888,220 | $2.50M |
| Ming-Fu (alan) Chiang | Director | 775,842 | $2.19M |
| Thomas C Chen | CEO | 676,784 | $1.91M |
| Keithly Garnett | CFO | 281,410 | $793.58K |
| Yousha Neman-Ebrahim | Chief Clinical Officer | 134,760 | $380.02K |
| David Jr. Suh | Chief Accounting Officer | 111,866 | $315.46K |
| Jim Delshad | Director | 50,260 | $141.73K |
| Steven L. Giannotta | Director | 50,160 | $141.45K |
| Nasim Shomali | Director | 50,160 | $141.45K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NTHI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.